Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram

Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of psychopharmacology (Oxford) 2012-05, Vol.26 (5), p.677-688
Hauptverfasser: Stoy, Meline, Schlagenhauf, Florian, Sterzer, Philipp, Bermpohl, Felix, Hägele, Claudia, Suchotzki, Kristina, Schmack, Katharina, Wrase, Jana, Ricken, Roland, Knutson, Brian, Adli, Mazda, Bauer, Michael, Heinz, Andreas, Ströhle, Andreas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 688
container_issue 5
container_start_page 677
container_title Journal of psychopharmacology (Oxford)
container_volume 26
creator Stoy, Meline
Schlagenhauf, Florian
Sterzer, Philipp
Bermpohl, Felix
Hägele, Claudia
Suchotzki, Kristina
Schmack, Katharina
Wrase, Jana
Ricken, Roland
Knutson, Brian
Adli, Mazda
Bauer, Michael
Heinz, Andreas
Ströhle, Andreas
description Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment.
doi_str_mv 10.1177/0269881111416686
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020852937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0269881111416686</sage_id><sourcerecordid>1020852937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-8534528cccc907775615acec638492409e998383f303b2e82ae69a7a91c43e173</originalsourceid><addsrcrecordid>eNqNkU2LFDEQhoMo7rh69yQBEby05vvjKIu6woIXPTe1mWrN0t1pk_Qs41_wT5thxg8WBOuSUO9Tb1VShDzl7BXn1r5mwnjneAvFjXHmHtlwZXhnhdP3yeYgdwf9jDwq5YYxbpTRD8mZ4F4YJeSG_LjcLykjhBp3se5pGugO55phpKXmCHWdaE23kLeFxjk0Ke6wSXFax9gydJ0n3MYAFbd0i0vGUtptgRobW-ic8gRj_I6FwlAx09qa1alp9DbWrxRLiBXGtGSYHpMHA4wFn5zOc_L53dtPF5fd1cf3Hy7eXHVBCVc7p6XSwoUWnllrteEaAgYjnfJCMY_eO-nkIJm8FugEoPFgwfOgJHIrz8nLo--S07cVS-2nWAKOI8yY1tJzJpjTwsv_QbmTyjLlGvr8DnqT1jy3h_RcKy-1UtY3ih2pkFMpGYd-yXGCvG9W_WGn_d2dtpJnJ-P1uv3174JfS2zAixMAJcA4ZJhDLH847ZWW5jBhd-QKfMG_pvtX45_eJbe6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1549354479</pqid></control><display><type>article</type><title>Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Stoy, Meline ; Schlagenhauf, Florian ; Sterzer, Philipp ; Bermpohl, Felix ; Hägele, Claudia ; Suchotzki, Kristina ; Schmack, Katharina ; Wrase, Jana ; Ricken, Roland ; Knutson, Brian ; Adli, Mazda ; Bauer, Michael ; Heinz, Andreas ; Ströhle, Andreas</creator><creatorcontrib>Stoy, Meline ; Schlagenhauf, Florian ; Sterzer, Philipp ; Bermpohl, Felix ; Hägele, Claudia ; Suchotzki, Kristina ; Schmack, Katharina ; Wrase, Jana ; Ricken, Roland ; Knutson, Brian ; Adli, Mazda ; Bauer, Michael ; Heinz, Andreas ; Ströhle, Andreas</creatorcontrib><description>Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment.</description><identifier>ISSN: 0269-8811</identifier><identifier>EISSN: 1461-7285</identifier><identifier>DOI: 10.1177/0269881111416686</identifier><identifier>PMID: 21926423</identifier><identifier>CODEN: JOPSEQ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antidepressive Agents, Second-Generation - therapeutic use ; Basal Ganglia - drug effects ; Basal Ganglia - physiopathology ; Biological and medical sciences ; citalopram ; Citalopram - therapeutic use ; Clinical outcomes ; Depression ; Depressive Disorder, Major - drug therapy ; Depressive Disorder, Major - physiopathology ; Female ; Functional magnetic resonance imaging ; Humans ; Information processing ; Intelligence ; Inventories ; Magnetic Resonance Imaging - methods ; Male ; Medical sciences ; Mental depression ; Mood disorders ; Motivation ; Neostriatum ; Neuroimaging ; Neuroimaging - methods ; Neuropharmacology ; NMR ; Nuclear magnetic resonance ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychotherapy ; Reinforcement ; Serotonin uptake inhibitors ; Serotonin Uptake Inhibitors - therapeutic use ; Smoking</subject><ispartof>Journal of psychopharmacology (Oxford), 2012-05, Vol.26 (5), p.677-688</ispartof><rights>The Author(s) 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Sage Publications Ltd. May 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-8534528cccc907775615acec638492409e998383f303b2e82ae69a7a91c43e173</citedby><cites>FETCH-LOGICAL-c428t-8534528cccc907775615acec638492409e998383f303b2e82ae69a7a91c43e173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0269881111416686$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0269881111416686$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25945368$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21926423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stoy, Meline</creatorcontrib><creatorcontrib>Schlagenhauf, Florian</creatorcontrib><creatorcontrib>Sterzer, Philipp</creatorcontrib><creatorcontrib>Bermpohl, Felix</creatorcontrib><creatorcontrib>Hägele, Claudia</creatorcontrib><creatorcontrib>Suchotzki, Kristina</creatorcontrib><creatorcontrib>Schmack, Katharina</creatorcontrib><creatorcontrib>Wrase, Jana</creatorcontrib><creatorcontrib>Ricken, Roland</creatorcontrib><creatorcontrib>Knutson, Brian</creatorcontrib><creatorcontrib>Adli, Mazda</creatorcontrib><creatorcontrib>Bauer, Michael</creatorcontrib><creatorcontrib>Heinz, Andreas</creatorcontrib><creatorcontrib>Ströhle, Andreas</creatorcontrib><title>Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram</title><title>Journal of psychopharmacology (Oxford)</title><addtitle>J Psychopharmacol</addtitle><description>Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Basal Ganglia - drug effects</subject><subject>Basal Ganglia - physiopathology</subject><subject>Biological and medical sciences</subject><subject>citalopram</subject><subject>Citalopram - therapeutic use</subject><subject>Clinical outcomes</subject><subject>Depression</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Depressive Disorder, Major - physiopathology</subject><subject>Female</subject><subject>Functional magnetic resonance imaging</subject><subject>Humans</subject><subject>Information processing</subject><subject>Intelligence</subject><subject>Inventories</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Mood disorders</subject><subject>Motivation</subject><subject>Neostriatum</subject><subject>Neuroimaging</subject><subject>Neuroimaging - methods</subject><subject>Neuropharmacology</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychotherapy</subject><subject>Reinforcement</subject><subject>Serotonin uptake inhibitors</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Smoking</subject><issn>0269-8811</issn><issn>1461-7285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2LFDEQhoMo7rh69yQBEby05vvjKIu6woIXPTe1mWrN0t1pk_Qs41_wT5thxg8WBOuSUO9Tb1VShDzl7BXn1r5mwnjneAvFjXHmHtlwZXhnhdP3yeYgdwf9jDwq5YYxbpTRD8mZ4F4YJeSG_LjcLykjhBp3se5pGugO55phpKXmCHWdaE23kLeFxjk0Ke6wSXFax9gydJ0n3MYAFbd0i0vGUtptgRobW-ic8gRj_I6FwlAx09qa1alp9DbWrxRLiBXGtGSYHpMHA4wFn5zOc_L53dtPF5fd1cf3Hy7eXHVBCVc7p6XSwoUWnllrteEaAgYjnfJCMY_eO-nkIJm8FugEoPFgwfOgJHIrz8nLo--S07cVS-2nWAKOI8yY1tJzJpjTwsv_QbmTyjLlGvr8DnqT1jy3h_RcKy-1UtY3ih2pkFMpGYd-yXGCvG9W_WGn_d2dtpJnJ-P1uv3174JfS2zAixMAJcA4ZJhDLH847ZWW5jBhd-QKfMG_pvtX45_eJbe6</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Stoy, Meline</creator><creator>Schlagenhauf, Florian</creator><creator>Sterzer, Philipp</creator><creator>Bermpohl, Felix</creator><creator>Hägele, Claudia</creator><creator>Suchotzki, Kristina</creator><creator>Schmack, Katharina</creator><creator>Wrase, Jana</creator><creator>Ricken, Roland</creator><creator>Knutson, Brian</creator><creator>Adli, Mazda</creator><creator>Bauer, Michael</creator><creator>Heinz, Andreas</creator><creator>Ströhle, Andreas</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram</title><author>Stoy, Meline ; Schlagenhauf, Florian ; Sterzer, Philipp ; Bermpohl, Felix ; Hägele, Claudia ; Suchotzki, Kristina ; Schmack, Katharina ; Wrase, Jana ; Ricken, Roland ; Knutson, Brian ; Adli, Mazda ; Bauer, Michael ; Heinz, Andreas ; Ströhle, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-8534528cccc907775615acec638492409e998383f303b2e82ae69a7a91c43e173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Basal Ganglia - drug effects</topic><topic>Basal Ganglia - physiopathology</topic><topic>Biological and medical sciences</topic><topic>citalopram</topic><topic>Citalopram - therapeutic use</topic><topic>Clinical outcomes</topic><topic>Depression</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Depressive Disorder, Major - physiopathology</topic><topic>Female</topic><topic>Functional magnetic resonance imaging</topic><topic>Humans</topic><topic>Information processing</topic><topic>Intelligence</topic><topic>Inventories</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Mood disorders</topic><topic>Motivation</topic><topic>Neostriatum</topic><topic>Neuroimaging</topic><topic>Neuroimaging - methods</topic><topic>Neuropharmacology</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychotherapy</topic><topic>Reinforcement</topic><topic>Serotonin uptake inhibitors</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Smoking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stoy, Meline</creatorcontrib><creatorcontrib>Schlagenhauf, Florian</creatorcontrib><creatorcontrib>Sterzer, Philipp</creatorcontrib><creatorcontrib>Bermpohl, Felix</creatorcontrib><creatorcontrib>Hägele, Claudia</creatorcontrib><creatorcontrib>Suchotzki, Kristina</creatorcontrib><creatorcontrib>Schmack, Katharina</creatorcontrib><creatorcontrib>Wrase, Jana</creatorcontrib><creatorcontrib>Ricken, Roland</creatorcontrib><creatorcontrib>Knutson, Brian</creatorcontrib><creatorcontrib>Adli, Mazda</creatorcontrib><creatorcontrib>Bauer, Michael</creatorcontrib><creatorcontrib>Heinz, Andreas</creatorcontrib><creatorcontrib>Ströhle, Andreas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of psychopharmacology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stoy, Meline</au><au>Schlagenhauf, Florian</au><au>Sterzer, Philipp</au><au>Bermpohl, Felix</au><au>Hägele, Claudia</au><au>Suchotzki, Kristina</au><au>Schmack, Katharina</au><au>Wrase, Jana</au><au>Ricken, Roland</au><au>Knutson, Brian</au><au>Adli, Mazda</au><au>Bauer, Michael</au><au>Heinz, Andreas</au><au>Ströhle, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram</atitle><jtitle>Journal of psychopharmacology (Oxford)</jtitle><addtitle>J Psychopharmacol</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>26</volume><issue>5</issue><spage>677</spage><epage>688</epage><pages>677-688</pages><issn>0269-8811</issn><eissn>1461-7285</eissn><coden>JOPSEQ</coden><abstract>Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>21926423</pmid><doi>10.1177/0269881111416686</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0269-8811
ispartof Journal of psychopharmacology (Oxford), 2012-05, Vol.26 (5), p.677-688
issn 0269-8811
1461-7285
language eng
recordid cdi_proquest_miscellaneous_1020852937
source Access via SAGE; MEDLINE
subjects Adult
Adult and adolescent clinical studies
Antidepressive Agents, Second-Generation - therapeutic use
Basal Ganglia - drug effects
Basal Ganglia - physiopathology
Biological and medical sciences
citalopram
Citalopram - therapeutic use
Clinical outcomes
Depression
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - physiopathology
Female
Functional magnetic resonance imaging
Humans
Information processing
Intelligence
Inventories
Magnetic Resonance Imaging - methods
Male
Medical sciences
Mental depression
Mood disorders
Motivation
Neostriatum
Neuroimaging
Neuroimaging - methods
Neuropharmacology
NMR
Nuclear magnetic resonance
Pharmacology. Drug treatments
Psychiatric Status Rating Scales
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychotherapy
Reinforcement
Serotonin uptake inhibitors
Serotonin Uptake Inhibitors - therapeutic use
Smoking
title Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyporeactivity%20of%20ventral%20striatum%20towards%20incentive%20stimuli%20in%20unmedicated%20depressed%20patients%20normalizes%20after%20treatment%20with%20escitalopram&rft.jtitle=Journal%20of%20psychopharmacology%20(Oxford)&rft.au=Stoy,%20Meline&rft.date=2012-05-01&rft.volume=26&rft.issue=5&rft.spage=677&rft.epage=688&rft.pages=677-688&rft.issn=0269-8811&rft.eissn=1461-7285&rft.coden=JOPSEQ&rft_id=info:doi/10.1177/0269881111416686&rft_dat=%3Cproquest_cross%3E1020852937%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1549354479&rft_id=info:pmid/21926423&rft_sage_id=10.1177_0269881111416686&rfr_iscdi=true